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DOI 10.1016/j.ccr.2010.08.007SUMMARYIn vitro studies have shown that inhibition of ribosomal biogenesis can activate p53 through ribosomal
protein (RP)-mediated suppression of Mdm2 E3 ligase activity. To study the physiological significance of
the RP-Mdm2 interaction, we generated mice carrying a cancer-associated cysteine-to-phenylalanine
substitution in the zinc finger of Mdm2 that disrupted its binding to RPL5 and RPL11. Mice harboring this
mutation, retain normal p53 response to DNA damage, but lack of p53 response to perturbations in ribosome
biogenesis. Loss of RP-Mdm2 interaction significantly accelerates Em-Myc-induced lymphomagenesis.
Furthermore, ribosomal perturbation-induced p53 response does not require tumor suppressor p19ARF.
Collectively, our findings establish RP-Mdm2 interaction as a genuine p53 stress-signaling pathway acti-
vated by aberrant ribosome biogenesis and essential for safeguarding against oncogenic c-MYC-induced
tumorigenesis.INTRODUCTION
The p53 transcription factor interacts with a large number of
proteins and plays a central role in regulating cell growth, prolif-
eration, and apoptosis (Vogelstein et al., 2000). The function of
p53 is negatively controlled by Mdm2 (HDM2 in humans, hence-
forth as Mdm2), which itself is a transcriptional target of p53,
thus constituting an auto regulatory feedback loop (Picksley
and Lane, 1993). Mdm2 controls the activity of p53 and is
regulated in response to a multitude of stressors, one of these
stressors is the so-called nucleolar stress (also known as
ribosomal stress) (Rubbi and Milner, 2003). Previous evidence
demonstrates a nucleolar stress response to a low dose (5 nM)Significance
Several ribosomal proteins (RPs) have been shown to interact
vating p53. The physiological significance of these interactions
knockin mouse model provides in vivo evidence for a prevail
monitors the integrity of ribosome biogenesis and activates p5
the RP-Mdm2-p53 pathway as an important barrier, parallel
oncogenic c-MYC-induced tumorigenesis.
Canof actinomycin D (Act D) (Dai and Lu, 2004; Dai et al., 2004;
Jin et al., 2004), 5-fluorouracil (5-FU) (Gilkes et al., 2006; Sun
et al., 2007), serum depletion and contact inhibition (Bhat
et al., 2004), mycophenolic acid (MPA)-mediated depletion of
GTP (Sun et al., 2008), or interfering with nucleolar function by
ectopic overexpression of nucleostemin (Dai et al., 2008). At
low concentrations (e.g., <10 nM), Act D selectively inhibits
ribosomal biogenesis through inhibiting pol I-dependent tran-
scription of rRNA (Iapalucci-Espinoza and Franze-Fernandez,
1979; Perry and Kelley, 1970). 5-FU is a pyrimidine analog
whose metabolite, FUTP, is extensively incorporated into
RNA, disrupting normal RNA processing (Longley et al., 2003).
MPA inhibits de novo guanine nucleotide biosynthesis, leadingwith and inhibit the E3 ligase function of Mdm2, thereby acti-
, however, has not been established in vivo. The Mdm2C305F
ing p53 checkpoint mediated by RP-Mdm2 interaction that
3 when this process goes awry. This study also establishes
to the p19ARF-Mdm2-p53 signaling, for defending against
cer Cell 18, 231–243, September 14, 2010 ª2010 Elsevier Inc. 231
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de novo RNA synthesis (Allison, 2005). As the prime location for
ribosome biogenesis, the nucleolus is highly susceptible to
perturbations in the process of ribosome assembly, thereby
clarifying how nucleolar stress is often synonymous with ‘‘ribo-
somal stress.’’
Ribosome biogenesis is an essential cellular process that
involves three fundamental steps: coordinated expression of
ribosomal RNA (rRNA) and ribosomal protein (RP), processing
of rRNA, and assembly of the 40S and 60S ribosome subunits
(Perry, 2007). Perturbation of any step in this process is thought
to lead to nucleolar stress, triggering specific binding of Mdm2 to
several RPs, including L11 (Fumagalli et al., 2009; Lohrum et al.,
2003; Zhang et al., 2003), L23 (Dai et al., 2004; Jin et al., 2004),
and L5 (Dai and Lu, 2004). Increased binding of ribosomal
proteins to Mdm2 leads to p53 stability and transactivation.
In addition to L5, L11, and L23, additional ribosomal proteins
such as S7 (Chen et al., 2007; Zhu et al., 2009) and L26
(Ofir-Rosenfeld et al., 2008) have also been shown to interact
with Mdm2. The consequence of the S7-Mdm2 interaction
resembles that of the other RPs in terms of binding to Mdm2
and activation of p53. However, surprising findings show that
MdmX, a homolog of Mdm2, can facilitate S7’s suppression of
Mdm2 and that S7, itself a substrate for Mdm2 ubiquitination,
acts as both an effector and affector of Mdm2 (Zhu et al.,
2009). The interaction of L26 with Mdm2 appears to perform
a different function. L26 was found to increase the translational
rate of p53 mRNA through binding to its 50 untranslated region
(UTR) and in this case Mdm2 acts as an E3 ubiquitin ligase
for ubiquitylation and degradation of L26, thereby inhibiting
p53 translation (Ofir-Rosenfeld et al., 2008). Collectively, these
findings indicate that RPs could play a pivotal role in mediating
a p53 response to nucleolar stress (reviewed in Zhang and
Lu, 2009).
Mdm2 contains three highly conserved regions: the N
terminus, the C terminus, and the central zinc finger area. The
N-terminal conserved domain is important for p53 binding. The
C-terminal domain contains a RING finger essential for the E3
ubiquitin ligase function of Mdm2. The function of the central
acidic domain, including a highly conserved C4 zinc finger, is
not fully understood. Intriguingly, several small basic proteins
that function to inhibit Mdm2, including p19ARF and each of
the aforementioned ribosomal proteins, all interact with the
conserved central acidic domain of Mdm2 (Figure 1A), suggest-
ing that this region might serve as a site for receiving and inte-
grating various Mdm2-regulatory signals into the p53 pathway
(Dai et al., 2006).
mdm2 gene amplification is the predominant mechanism
ascribed to oncogenic activation and has been detected in
many types of human cancers including soft tissue sarcomas
(Oliner et al., 1992) and brain tumors (Corvi et al., 1995; Reifen-
berger et al., 1993). In addition to gene amplification and protein
overexpression, mutations within the mdm2 gene have been
reported in several types of human cancers (Schlott et al.,
1997; Tamborini et al., 2001). Intriguingly, many of the cancer
associated Mdm2 mutations occur at or near the central zinc
finger, including point mutations altering one of the conserved
zinc-coordinating cysteines and truncations around the zinc
finger. In vitro studies have shown that mutations at the zinc-232 Cancer Cell 18, 231–243, September 14, 2010 ª2010 Elsevier Incoordinating cysteine residues disrupts Mdm2 binding to L5
and L11, and as a result diminishes the capacity of Mdm2 to
respond to nucleolar stress (Lindstrom et al., 2007). However,
despite recent evidence frommultiple laboratories corroborating
a putative RP-Mdm2-p53 signaling pathway, the validity of RP
mediated signaling to p53 has yet to be demonstrated in vivo.
The current study was designed to investigate this.
RESULTS
Generation of Mdm2C305F Mice
To investigate the physiological relevance of zinc finger muta-
tion, we generated mice bearing a cancer-associated Cys-to-
Phe substitution in one of the zinc-coordinating residues of
Mdm2. The targeting construct, containing a C305F substitution
and a new Spe1 restriction site (Figure 1B), was recombined into
themdm2 locus of 129/Sv embryonic stem (ES) cells. Successful
targeting of mdm2 allele was identified by Southern blotting of
genomic DNA isolated from the ES cells (Figure 1C), and was
confirmed by Spe1 digestion of PCR-amplified genomic DNA
(Figure 1D). The ES cells were microinjected into C57BL/6 blas-
tocysts to produce chimeras. Chimera males were mated with
C57BL/6 females to produce germline transmission of the
Mdm2C305F allele. The targeted allele was reconfirmed through
direct sequencing of the genomic DNA after germline transmis-
sion was obtained (data not shown). The neomycin resistance
gene (neo) was removed from the targeted allele by crossing
neo-Mdm2C305F heterozygousmicewith transgenicmice ubiqui-
tously expressing Cre recombinase. The resulting Mdm2+/C305F
heterozygous mice were then backcrossed with C57BL/6 mice
for five generations to generate near congenic (97% pure)
C57BL/6 Mdm2+/C305F mice.
Mdm2C305F Mice Have a Normal Lifespan
The heterozygous Mdm2+/C305F mice were intercrossed to
generate homozygous Mdm2C305F/C305F mice. Of 151 pups
born from the intercross an accurate Mendelian inheritance
was observed (Figure 1E). A survival study was carried out to
examine the effect of Mdm2C305F mutation on longevity. At least
17 animals were included for each genotype, 2–4 animals of the
same sex were housed in each cage, and the longevity of these
mice were monitored over a 900-day period. Kaplan-Meier
survival curve shows a similar survival rate among wild-type,
Mdm2+/C305F and Mdm2C305F/C305F mice (Figure 1F). Addition-
ally, Mdm2+/C305F or Mdm2C305F/C305F mice did not exhibit
noticeable differences in body weight, pathophysiological
defects or predisposition to spontaneous tumors from those of
the wild-type mice.
Mdm2C305F Mutation Disrupts L5 and L11 Binding
To examine the binding activity of the endogenous Mdm2C305F
mutant protein, mouse embryonic fibroblasts (MEFs) were iso-
lated at embryonic day 13.5 (E13.5) and an immunoprecipita-
tion-coupled western blot (IP-western) assay was carried out.
Consistent with previous in vitro studies (Lindstrom et al.,
2007), Mdm2C305F failed to bind L5 and L11 (Figure 2A).
In contrast, Mdm2C305F was able to bind L23 and p53 (Figures
2A and 2B). The L23-Mdm2 binding can be shown only by IP
of L23 but not by IP of Mdm2 due to a potential interference ofc.
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Figure 1. Generation and Analysis of
Mdm2C305F Knockin Mice
(A) A diagram of Mdm2 protein and approximate
binding domains for p53, ARF, and several ribo-
somal proteins.
(B) Schematic representation of Mdm2C305F tar-
geting strategy. Exons 7–12 of Mdm2 are shown
in black boxes. The targeting vector contains
negative selection marker thymidine kinase (TK)
and positive selection marker neomycin resistant
gene (neo). Two loxP sites are shown as triangles.
(C) Southern blot analysis was used to screen ES
clones for the targeted allele. BamH1 digestion
generates a 9.5 kb fragment from the wild-type
allele. The targeted allele gives rise to two
BamH1 fragments of 4.8 kb and 6.5 kb, respec-
tively.
(D) DNA from ES cells positive for the recombined
allele identified was analyzed for the presence of
Mdm2C305F mutation by PCR amplification and
Spe1 digestion.
(E) Shown are expected and observed birth ratios
from a total of 151 mice obtained from Mdm2+/m
intercross.
(F) Kaplan-Meier survival curve for Mdm2+/+ (+/+),
Mdm2+/C305F (+/m) and Mdm2C305F/C305F (m/m)
mice are shown.
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assess E3 ubiquitin ligase activity of Mdm2C305F, we carried
out p53 half-life assay using early-passage MEF cells. The half-
life of p53 was 30 min under unstressed conditions in both
wild-type and Mdm2C305F mutant cells (Figure 2C). Likewise,
the half-life of Mdm2 itself was found to be also comparable in
both wild-type and mutant cells, at 10 min (Figure 2D). Thus,
the C305F mutation in the zinc finger does not affect the degra-
dation of p53 or Mdm2 itself. We have noticed that the typical
doublet-banding pattern of Mdm2 was somewhat altered by
the zinc finger mutation, with the mutant Mdm2C305F showing
a stronger top band whereas the wild-type Mdm2 showing
a stronger bottom band (Figure 2D). The nature of the alteration
remains to be clarified.Cancer Cell 18, 231–243, SeMdm2C305F Mice Retain a Normal
p53 Response to DNA Damage
To assess the effect of Mdm2C305F muta-
tion on p53 response to DNA damage, we
examined p53 protein levels in MEFs.
Early passage MEFs were either left
untreated (Control) or treated with 1 mM
of doxorubicin (Dox) or 50 J/m2 of ultravi-
olet C (UV) light, and p53 was examined
by western blotting. As shown in Fig-
ure 3A, p53 level was increased to
comparable levels among Mdm2+/+,
Mdm2+/C305F, and Mdm2C305F/C305F MEFs
after Dox or UV treatment. To ascertain
that DNA damage-induced p53 trans-
criptional activity has not been affected,
we examined Mdm2 and p21, two arche-
typal p53 transcriptional targets, in MEFstreated with an increasing amount of Dox. The levels of Mdm2
and p21 increased progressively along with increasing amount
of Dox (Figure 3B). Importantly, the levels of Mdm2 and p21
were very comparable between the wild-type and the mutant
cells at each corresponding Dox dosage.
We next examined p53 response to DNA damage in mouse
tissues. Mouse whole-body g-irradiation causes p53-dependent
growth arrest and apoptosis in organs that are sensitive to radi-
ation, such as intestinal epithelium, spleen, bone marrow, and
thymus (Bouvard et al., 2000). Differential responses to irradia-
tion reflect changes of p53 function and can be used as a test
for p53 activity in vivo (Komarova et al., 2000). We subjected
mice to 8-Gy whole-body g-irradiation, and the stabilization
and activation of p53 was assessed in thymus and spleenptember 14, 2010 ª2010 Elsevier Inc. 233
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Figure 2. Characterization of Mdm2C305F
Mutant Protein
(A) Mdm2+/+ and Mdm2m/m MEFs were treated
with 5 nM Act D and lysates were immunoprecip-
itated (IP) with anti-Mdm2 antibody and immuno-
blotted (IB) for Mdm2, p53, L5 and L11 as indi-
cated. Loading represents 5% of total lysate
used for IP.
(B) MEFs were treated as in (A) and lysates were
analyzed as indicated.
(C) Half-life of p53 in Mdm2+/+ and Mdm2m/m
MEFs. Half-life assay was carried out using early
passage (P1) MEFs treated with cycloheximide
(50 mg/ml) and harvested with SDS lysis buffer at
the indicated time points. Relative amount of
p53 was quantified by densitometry, normalized
to actin, and plotted.
(D) Half-life of Mdm2 and Mdm2C305F. MEFs were
treated and analyzed as in (C) for Mdm2.
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slightly increased after g-irradiation in both spleen and thymus.
The level of p21, on the other hand, was significantly increased,
and the increase was similar in organs of the wild-type and the
Mdm2C305F/C305F mice, consistent with results from MEF cells.
We have noticed that the basal levels of p53 and p21 in
unstressed mutant organs are somewhat elevated, the reason
for which has not been determined. We also investigated DNA
damage-induced apoptosis by TUNEL assay. With g-irradiation,
extensive apoptosis was observed and the levels of apoptosis in
organs isolated from wild-type and Mdm2C305F/C305F mice were
essentially identical (Figure 3D). Together, these results support
a notion that the p53 DNA damage response is not affected by
Mdm2C305F mutation.234 Cancer Cell 18, 231–243, September 14, 2010 ª2010 Elsevier Inc.Mdm2C305F Mutation Attenuates
p53 Response to Ribosome
Biogenesis Stress
Given that theMdm2C305F mutant protein
does not interact with L5 and L11
(Figure 2), we sought to determine if
a low level Act D-induced p53 activation
might be attenuated. First, we examined
a time-course induction of p53 in MEFs.
We observed induction of p53 in the
wild-type MEFs within 1–2 hr of Act D
treatment that was further increased
and sustained until termination of the
experiment at 12 hr (Figure 4A). In
contrast, only a slight induction of p53
at 2 and 4 hr time points was observed
Mdm2C305F/C305F MEFs (Figure 4A). The
intensity of p53 induction correlated
with Mdm2C305F gene dosage with the
wild-type cells exhibiting the highest
level of p53 induction and the heterozy-
gous cells showing an intermediate
induction (Figure 4B). Moreover, we
found that a high dose of Act D, 200 nM,
elicited equivalent p53 response inMEFs of all genotypes (Figure 4C), consistent with a notion
that Act D at this concentration causes DNA double strand
breaks (Ljungman et al., 1999), and that Mdm2C305F/C305F cells
retain a normal p53 response to DNA damage (Figure 3).
Next, we investigated p53 response to Act D in a more phys-
iological setting of mouse skin, which has been extensively used
to characterize effects of Act D on cell growth (Bates et al., 1968).
The dorsal skins of wild-type and Mdm2C305F/C305F littermate
mice were treated topically with a single dose of 1 mg Act D dis-
solved in 0.2 ml of acetone, which specifically inhibits ribosomal
RNA synthesis with little effect on mRNA or protein synthesis in
the mouse skin (Flamm et al., 1966). Negative control mice and
8-Gy g-irradiated mice were mock treated with 0.2 ml of
acetone. Eighteen hours after the treatment a portion of the
BD
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Figure 3. Mdm2C305F Mice Retain Intact p53
Response to DNA Damage
(A) Mdm2+/+, Mdm2m/+, and Mdm2m/m MEFs were
mock treated (Control) or treated with 1 mM doxo-
rubicin (Dox) or 50 J/m2 of ultraviolet C (UV). The
cells were harvested 18 hr posttreatment and
immunoblotted for p53 and actin.
(B) Mdm2+/+ and Mdm2m/m MEFs were treated
with increasing dosage of Dox for 18 hr. Cell
extracts were analyzed for p53, p21, and Mdm2.
(C) Induction of p21 in spleen and thymus after
g-irradiation. Spleen and thymus were harvested
from Mdm2+/+ and Mdm2m/m mice 18 hr after
8-Gy whole body g-irradiation. Protein extracts
were assayed for protein levels of p53, p21, and
Actin. Spleen protein extract from a p53/mouse
was used as a negative control.
(D) Apoptotic response to whole body g-irradia-
tion. The level of apoptosis in spleen and thymus
was determined by TUNEL assay, carried out on
paraffin embedded tissues from mice 18 hr after
receiving 8-Gy of whole body g-irradiation. The
percentage of TUNEL positive cells was quantified
and averaged from three identically treated mice.
Scale bars represent 75 mm. Error bars in all cases
represent ± standard deviation.
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Figure 4. Mdm2C305F Mice Demonstrate Attenuated p53 Response to Ribosome Biogenesis Stress
(A) MEFs were treated with 5 nM Act D and harvested at indicated time points. Cell lysates were immunoblotted for p53 and actin.
(B) Mdm2+/+, Mdm2+/m, and Mdm2m/m MEFs were either mock treated or treated with 5 nM Act D for 12 hr before harvesting for western blot analysis.
(C) p53 response to a DNA damaging dosage of Act D in Mdm2m/m MEFs. MEFs were treated with 200 nM Act D for 12 hr and analyzed for p53.
(D) Mouse dorsal skins were treated topically with 200 ml of acetone (Control) or Act D (1 mg/200 ml acetone). Protein lysates were prepared from snap frozen
skin collected 18 hr after the treatment by epidermal scrapes and analyzed for p53. As a positive control, dorsal skins were treated with acetone and followed
immediately by whole body 8-Gy g-irradiation (IR), and the skin cells were collected 18 hr after the treatment.
(E) Early passage MEFs were either mock treated or treated with 5 nM Act D for 18 hr. Cell cycle distribution was determined by flow cytometry using propidium
iodide (PI) staining. Samples were run in triplicate with a minimum of 15,000 cells analyzed for each treatment.
(F) BrdU incorporation analysis inMdm2m/m keratinocytes. Mouse dorsal skins were treated as in (D) and fixed in formalin 18 hr posttreatment. BrdU incorporation
was determined by immunohistochemistry. For quantification, BrdU positive interfollicular basal keratinocytes from 15 representative 200 mm fields were
counted. Three mice were used for each group. Asterisk indicates p value of <0.01 determined by Tukey’s multiple comparison tests.
(G) p53 response to 5-FU and MPA. MEFs were treated with 1 mM 5-FU or 2 mM MPA for 12 hr and assessed for p53 by western blotting.
Error bars in all cases represent ± standard deviation.
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analysis of epidermal lysates demonstrated that Act D-induced
stabilization of p53 was diminished in Mdm2C305F/C305F keratino-
cytes, whereas the response to g-irradiation remained intact
(Figure 4D).
To determine Act D response on cell proliferation, we carried
out cell cycle analysis. We treated early passage wild-type
and Mdm2C305F/C305F MEFs with 5 nM Act D for 18 hr and exam-
ined the percentage of cells in S phase by fluorescence-
activated cell sorting (FACS). The FACS analysis showed that
the Mdm2C305F/C305F cells had a weakened cell cycle arrest
in response to Act D treatment (Figure 4E). Consistent results
were obtained from BrdU (5-bromo-2-deoxyuridine) incorpora-
tion analysis of Act D treated dorsal mouse skins, inhibition of
BrdU incorporation was less pronounced in Mdm2C305F/C305F
keratinocytes than in wild-type keratinocytes (Figure 4F).
We also examined if the Mdm2C305F mutation confers resis-
tance to 5-FU and MPA, two known inhibitors of ribosome
biogenesis. We treated MEFs with 5-FU and MPA and deter-236 Cancer Cell 18, 231–243, September 14, 2010 ª2010 Elsevier Inmined p53 stabilization by Western blotting. Similar to the
observations with Act D, p53 induction was attenuated in
Mdm2C305F/C305F MEFs in a gene dosage dependent manner
(Figure 4G). Together, these results indicate that Mdm2 interac-
tion with L5/L11 is important for transducing cellular stress
signals that specifically impinge on ribosomal biogenesis, but
not DNA damage, to p53.
Myc-Induced Lymphomagenesis Is Accelerated
by Mdm2C305F Mutation
c-MYCupregulates ribosome biogenesis through direct transac-
tivation of many nucleolar proteins involved in ribosome
biogenesis (Ruggero and Pandolfi, 2003). To determine the
role of RP-Mdm2-p53 signaling in tumorigenesis, we crossed
Mdm2C305F/C305F mice with Em-Myc transgenic mice that consti-
tutively express c-MYC in B cell lineage and develop B cell
lymphoma at an early age (Adams et al., 1985). Littermates
animals (Em-Myc;Mdm2+/+, Em-Myc;Mdm2+/C305F, and Em-Myc;
Mdm2C305F/C305F) were monitored daily for signs of morbidityc.
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Figure 5. Myc-Induced Lymphomagenesis
Is Accelerated by Mdm2C305F Mutation
(A) Survival of Em-Myc transgenic mice. Kaplan-
Meier survival curve shows a median survival of
20, 15, and 9 weeks for Em-Myc;Mdm2+/+ (+/+,
n = 24), Em-Myc;Mdm2+/m (+/m, n = 27), and Em-
Myc;Mdm2m/m (m/m, n = 18) mice, respectively.
(B) Lymphoma onset in Em-Myc;Mdm2m/m mice.
Image shows dissection of a 58-day old Em-
Myc;Mdm2m/m mouse with typical enlargement
of liver, spleen, thymus, and lymph nodes,
including enlargement of Peyer’s patches and
mesenteric lymph nodes.
(C) Extracts from spleen and thymus of wild-type
(+/+) and tumor-bearing Em-Myc transgenic mice
were analyzed for L5 and L11.
(D) Accumulation of L11 in nucleus in Em-Myc
transgenic mouse splenocytes. Lysates of spleno-
cytes from wild-type and nontumor-bearing
Em-Myc transgenic mice were subjected to
fractionation as described in Experimental Proce-
dures. The total (Total), cytoplasmic (Cyto), nucle-
oplasmic (NP), and nucleolar (NO) fractions were
isolated and analyzed for L11. Actin (cytoplasmic)
and histone H3 (nuclear) were used as fraction-
ation markers.
(E) L11-Mdm2 binding in Em-Myc transgenic sple-
nocytes. Lysates from spleens of 4-week-old,
nontumor-bearing mice were immunoprecipitated
with anti-Mdm2 antibody and immunoblotted as
indicated. Loading represents 5% of total lysate
used for IP.
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studies, the Em-Myc transgenic mice with wild-type Mdm2 had
a median survival time of 20 weeks. The survival of Em-Myc;
Mdm2C305F/C305F compound mice, however, was significantly
shortened, showing a median survival of 9 weeks. An interme-
diate, yet significant, decrease in survival was observed in
Em-Myc;Mdm2+/C305F heterozygous compound mice, showing
a median survival of about 15 weeks (Figure 5A). Tumors arising
from the Em-Myc;Mdm2C305F/C305F mice presented with typical
lymphadenopathy (Figure 5B), and were phenotypically indistin-
guishable from those occurring in Em-Myc;Mdm2+/+mice. These
results suggest that the RP-Mdm2-p53 signaling, in addition to
p19ARF-Mdm2-p53 signaling, may be another stress response
barrier against Myc-induced lymphomagenesis.
To determine the mechanism leading to accelerated
lymphomagenesis in the Em-Myc;Mdm2C305F/C305F compound
mice, we isolated spleen and thymus tissues from tumor-
bearing Em-Myc;Mdm2+/+, Em-Myc;Mdm2+/C305F, and Em-Myc;Cancer Cell 18, 231–243, SeMdm2C305F/C305F animals, as well as
from age-matched nontransgenic wild-
type mice, and determined protein levels
of L5 and L11. In agreement with recent
studies showing c-MYC driving overex-
pression of ribosomal proteins (Boon
et al., 2001; Coller et al., 2000; Menssen
and Hermeking, 2002), we found that
the levels of L5 and L11 were highly
elevated in tissues expressing Em-Myc,and the elevation is irrespective of the Mdm2 C305F mutation
(Figure 5C). We also observed similar upregulation (Zhu et al.,
2009)of several other ribosomal proteins including L23, L26,
S9, and S6 (data not shown). We noticed that the actin level
appears to be lower in organs expressing Em-Myc when lysates
containing equal amount of total protein were analyzed using
immunoblotting. Therefore, in this case, actin-based loading
control would only underestimate the extent of L5/L11 overex-
pression. Prior study demonstrates that inhibition of ribosome
biogenesis induces translocation of L11 from nucleolus to nucle-
oplasm (Bhat et al., 2004), we therefore investigated if c-MYC
induced L5 and L11 overexpression could result in their nucleo-
plasmic accumulation, where they are in proximity with and can
bind to Mdm2. We isolated spleens from 4-week-old nontumor-
bearing animals. At this age the spleens from Em-Myc trans-
genics are moderately hyperplastic, but still comparable to
wild-type spleens in terms of organ size and morphology. We
fractionated splenocyte lysates into total (TO), cytoplasmicptember 14, 2010 ª2010 Elsevier Inc. 237
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Figure 6. p19ARF Is Dispensable for p53 Response to Nucleolar Stress
(A) Oncogenic c-MYC induction of p53 in Mdm2C305F mice. Extracts from spleens of 4-week-old, non-tumor-bearing Em-Myc;Mdm2+/+ and Em-Myc;Mdm2m/m
transgenics as well as from their nontransgenic counterparts were analyzed for p53, p19ARF, and L11. Two mice are used in each group.
(B) Myc induction of p53 in the absence of p19ARF. Early passage wild-type, Mdm2m/m and p19ARF/ MEFs were infected with retrovirus expressing either
pBabe vector or pBabe-c-MYC, selected by puromycin for 3 days, then allowed to recover for 48 hr before harvesting for western analysis.
(C) Early passage wild-type and p19ARF/ MEFs were treated with 5 nM Act D and harvested at the indicated time points. Cell lysates were analyzed for
indicated proteins.
(D) p53 response toMPA in p19ARF/MEFs. Early passage wild-type and p19ARF/MEFswere treated with 2 mMMPA for 12 hr, then harvested and analyzed
for p53.
(E) L11-Mdm2 and p19ARF-Mdm2 interaction in Act D treated MEFs. Early passage wild-type, Mdm2m/m and p19ARF/MEFs were treated with 5 nM Act D for
4 hr. Cell lysates were immunoprecipitated with anti-Mdm2 antibody and immunoblotted as indicated. Loading represents 5% of total lysate used for IP.
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examined L11 protein levels. Splenocytes isolated from tumor-
free, young Em-Myc transgenics expressed a higher level of total
L11 than do the nontransgenics (Figure 5D, compare lanes
1 and 2). Importantly, L11 was more prominent in the NP fraction
of Em-Myc transgenic splenocytes than of nontransgenic
splenocytes (Figure 5D, compare lanes 5 and 6). To further
determine the consequence of increased L11 in the nucleo-
plasm, we carried out anti-Mdm2 IP-western assay with spleens
isolated from nontumor-bearing Em-Myc;Mdm2C305F/C305F mice
and from control Em-Myc;Mdm2+/+ littermates. As expected,
Mdm2 interacted with L11 in lysates isolated from the Em-
Myc;Mdm2+/+ splenocytes; whereas the L11 in Em-Myc;
Mdm2C305F/C305F splenocytes, even though expressed to a
higher level than in Em-Myc;Mdm2+/+ splenocytes, showed
very little interactions with Mdm2 (Figure 5E). Collectively, these
data demonstrate that loss of L11-Mdm2 interaction due to the
Mdm2 zinc finger C305F mutation accelerated oncogenic
c-MYC-induced lymphomagenesis. The data also show that in
c-MYC overexpressing cells L11 is highly expressed and
enriched in the nucleus where it can interact with Mdm2, but
not with Mdm2C305F. Altogether, this suggests that disabling
the L11-Mdm2 interaction can compromise, at least in part,
p53 response to oncogenic c-MYC.238 Cancer Cell 18, 231–243, September 14, 2010 ª2010 Elsevier Inp19ARF Is Not Required for p53 Response to Ribosomal
Stress
We have noticed that the median survival of Em-Myc;
Mdm2C305F/C305Fmice (9 weeks; Figure 5A) is very similar to that
of Em-Myc;p19ARF/ mice (8 weeks) (Eischen et al., 1999).
We speculated that the p53 signaling mediated by RP-Mdm2
interaction and by p19ARF-Mdm2 interaction are parallel
pathways both required for anti-Myc-induced tumorigenesis,
elimination of either one results in accelerated tumor formation.
Alternatively, the two pathways may function in a linear fashion,
and mutations in Mdm2 that disrupt RP binding also affect
p19ARF function. To gain insight into possible interlink between
the two pathways, we first determined if p19ARF mediated
oncogenic signaling is compromised by the Mdm2 mutation.
To reduce individual variations duplicate mice were used
in each sample group. We isolated splenic extracts from
4-week-old nontumor-bearing Em-Myc;Mdm2+/+ and Em-Myc;
Mdm2C305F/C305F transgenics, as well as from their nontrans-
genic counterparts. The extracts were immunoblotted for L11,
p19ARF, and p53. In line with a previous study (Eischen et al.,
1999), Em-Myc expression resulted in elevated p19ARF expres-
sion in splenic B cells (Figure 6A, lanes 5 and6). Elevated
p19ARF expression was also observed in transgenic Mdm2C305F
mutant mice (Figure 6A, lanes 7 and 8), indicating that c-MYCc.
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binding. Importantly, we observed evident p53 induction in
spleens of Em-Myc;Mdm2+/+ transgenics, but less so in spleens
of Em-Myc;Mdm2C305F/C305Fmice. This is consistentwith a notion
that the RP-Mdm2-p53 pathway is important in oncogenic
c-MYC induction of p53.
Whereas sustained c-MYC expression elicits a p19ARF medi-
ated p53 response, additional p19ARF independent mecha-
nisms of c-MYC induction of p53 exist (Zindy et al., 1998).
Consistently, we found that both Mdm2C305F/C305F and
p19ARF/ MEFs transiently expressing c-MYC had compa-
rable elevated p53 levels, but was lower than that of wild-type
MEFs (Figure 6B), suggesting that the RP-Mdm2-p53 and the
p19ARF-Mdm2-p53 pathways act independently and are each
contributing to c-MYC induction of p53. To further ascertain
that the ribosomal stress-induced p53 is through a p19ARF
independent mechanism, we investigated p53 induction in
p19ARF/ MEF cells treated with Act D. Western blotting
demonstrated that in both wild-type and p19ARF/ MEF cells
p53 is induced similarly by a low level of Act D at comparable
kinetics (Figure 6C). Furthermore, we noticed that Mdm2,
a p53 target, was also induced with similar kinetics. Similar
results were also obtained by treating cells with MPA
(Figure 6D). Hence, the data indicate that p19ARF is not required
for ribosomal inhibition-induced p53 activation. Finally, we
examined Mdm2-p19ARF interaction in Act D treated
Mdm2C305F mutant MEFs. Act D treatment resulted in high-level
expression of p53 and Mdm2 in wild-type but not Mdm2C305F
MEFs; the treatment also resulted in high-level expression of
p53 and Mdm2 in p19ARF null MEFs (Figure 6E, loading). Immu-
noprecipitation demonstrated that Mdm2C305F mutant protein
interacts effectively with p19ARF, but not with L11 (Figure 6E,
lanes 3 and 4). Additionally, wild-type Mdm2 interacted with
L11 in p19ARF null MEFs and the interaction was enhanced on
Act D treatment (Figure 6E, lanes 5 and 6). It is worth mentioning
that the basal levels of p19ARF expression are slightly lower in
Mdm2C305F MEFs than in wild-type MEFs. Whether this is
a variation of MEF cell clones or is directly related to Mdm2C305F
mutation remains to be determined.
DISCUSSION
A number of ribosomal proteins, including L5, L11, L23, L26, S3,
and S7, have been shown to interact with and inhibit the E3
ligase function of Mdm2, thereby stabilizing and activating p53
(Chen et al., 2007; Dai and Lu, 2004; Dai et al., 2004; Jin et al.,
2004; Lohrum et al., 2003; Ofir-Rosenfeld et al., 2008; Zhang
et al., 2003; Zhu et al., 2009). The physiological significance of
the RP-Mdm2 interaction, however, has not been previously
studied in vivo. In this study, we generated and analyzed mice
carrying a C305F knockin mutation in the Mdm2 zinc finger.
The mutation disrupts the interaction of Mdm2 with L5 and
L11. Several important observations have been made from this
study.
An RP-Mdm2-p53 Signaling Pathway Sensing Inhibition
of Ribosome Biogenesis
The generation of Mdm2C305F mutant mice has allowed for
a detailed in vivo characterization for the role of RP-Mdm2Canbinding in p53 response to ribosome biogenesis perturbations.
Our data show that on DNA damage, the response of the mutant
mice is indistinguishable from that of wild-type animals in terms
of p53 activation, cell cycle arrest, and apoptosis. These data
indicate that the integrity of the Mdm2 zinc finger and thus the
binding of L5 and L11 are not required for p53 DNA damage
response. In contrast, p53 response to treating animals with
inhibitors that cause specifically inhibition of ribosomal biogen-
esis or nucleolar stress, but not DNA damage, is significantly
compromised in mutant animals. The failure of Mdm2C305F
animals to respond to nucleolar stress is in agreement with
previous in vitro studies, where knockdown of L11 results in an
attenuated p53 response to the same forms of inhibitions (Bhat
et al., 2004; Lohrum et al., 2003; Zhang et al., 2003). It also
corroborates our recent report that ectopically expressed
Mdm2C305F does not interact with L11, and that p53 activity
that has been suppressed by ectopically expressed Mdm2C305F
cannot be restored by L11 overexpression (Lindstrom et al.,
2007). Also consistent with in vitro data, we have found that
Mdm2C305F retains ability to interact with L23 and p53 as well
as with p19ARF. It seems that Mdm2 binding to L23, without
binding to L5 and L11, is insufficient for the response of P53 to
ribosomal stress. A recent study has shown that L11 cooperates
with L5 to inhibit Mdm2. When coexpressed the inhibitory
activity of L5 and L11 toward Mdm2 is enhanced (Horn and
Vousden, 2008). It remains to be studied if such a relationship
exists in the context of L23. Nonetheless, the bulk of studies
and available genetic models tend to favor L11 as the prime
mediator of p53 ribosomal stress response via inhibition of
Mdm2 (see below).
At the concentrations used in our study (5 nM), Act D specifi-
cally inhibits RNA pol I-dependent transcription (Iapalucci-
Espinoza and Franze-Fernandez, 1979; Perry and Kelley, 1970)
causing nucleolar stress, without causing DNA damage. Consis-
tently, genetic ablation of RNA Pol I transcription initiation factor
tif-IA, which abrogates Pol I transcription, elicits a p53 response
(Yuan et al., 2005). In this sense, low dose Act D treatment is akin
to genetic ablation of tif-IA. In fact, as is in the case with Act D
treatment, ablation of tif-IA in MEFs evokes breakdown of the
nucleolus, elicits the binding of L11 to Mdm2 and results in
p53 activation (Yuan et al., 2005). The Belly spot and tail (Bst)
mice, which have a point mutation in the ribosomal protein
gene rpl24, provide yet another genetic evidence for the exis-
tence of an RP-Mdm2-p53 signaling pathway. Mice heterozy-
gous for rpl24 (Bst+/mice) have impaired ribosomal biogenesis
leading to various congenital abnormalities (Oliver et al., 2004).
Interestingly, impairment of ribosome biogenesis in the Bst+/
mice elicits a p53 response that is also mediated by L11 inhibi-
tion of Mdm2 (Barkic et al., 2009). In conjunction with the work
presented herein, accumulating evidences from both in vitro
and in vivo studies point to existence of a bona fide p53 respon-
sive ribosomal biogenesis stress checkpoint (Figure 7A).
The L5/L11-Mdm2-p53 Signaling Pathway Is Required
for Preventing Oncogenic c-MYC Induced
Tumorigenesis
The proto-oncogene product c-MYC has been shown to directly
regulate ribosome biogenesis through the transcription of genes
encoding nucleolar proteins involved in ribosome biogenesis ascer Cell 18, 231–243, September 14, 2010 ª2010 Elsevier Inc. 239
A B
Figure 7. Models for RP-Mdm2-p53 Signaling in Response to Ribo-
somal Stress and Oncogenic c-MYC
(A) In response to ribosomal stress several ribosomal proteins, including L11
and L5, bind Mdm2 and inhibit its E3 ligase function, leading to stabilization
and activation of p53.
(B) Oncogenic c-MYC induces high expression of both p19ARF and ribosomal
proteins. The RP-Mdm2-p53 and p19ARF-Mdm2-p53 represent two parallel
signaling pathways in response to oncogenic c-MYC stimulation.
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However, it remains unknown whether c-MYC-driven ribosome
biogenesis is directly responsible for tumor promotion. We
postulated that the L11-Mdm2 interaction constitutes a check-
point for superfluous production of ribosomal proteins resulting
from oncogenic overexpression of c-MYC. To test this hypoth-
esis, we generated and analyzed Em-Myc;Mdm2C305F/C305F
mice. Em-Myc transgenic mice develop B cell lymphomas
(Adams et al., 1985), similar to those observed in human Burkitt’s
lymphomas bearing a translocated (t8;14) c-MYC allele (Alitalo
et al., 1987). Strikingly, we show that lymphomagenesis of Em-
Myc mice is greatly accelerated in the presence of Mdm2C305F.
Mechanistically, c-MYC induces overexpression of L11, which
accumulates in the nucleus and binds to Mdm2 but not
Mdm2C305F. The accelerated morbidity imparted by the
Mdm2C305F mutation is thus likely due to the loss of L11 binding
to Mdm2C305F. In regards to L23, it is clear that retention of L23
binding to Mdm2C305F is insufficient to compensate for loss of
L11 or L5 binding in deterring c-MYC lymphomagenesis in the
Em-Myc;Mdm2C305F/C305F mice. Moreover, although the genes
encoding for L11 and L23 are c-MYC target genes, L11 is
involved in a negative feedback loop with c-MYC, wherea L23
actually enables c-MYC to promote cell cycle progression (Dai
et al., 2007; Wanzel et al., 2008). Collectively, these results indi-
cate that the L11-Mdm2-p53 signaling plays an indispensable
role in deterring c-MYC-mediated tumorigenesis.
p19ARF-Mdm2-p53 and L11-Mdm2-p53 Are Parallel
Signaling Pathways
Our results raise an interesting question with regard to coopera-
tion between the p19ARF-Mdm2-p53 and the L11-Mdm2-p53
pathways. It is conceivable that p19ARF can impact ribosomal
biogenesis through inhibiting the processing of pre-ribosomal
RNA (Sugimoto et al., 2003), at least in part, through its interac-240 Cancer Cell 18, 231–243, September 14, 2010 ª2010 Elsevier Intion with and inhibiting the function of B23 (NPM) (Itahana et al.,
2003), an endoribonuclease essential for pre-rRNA processing
(Herrera et al., 1995; Savkur and Olson, 1998). Consequently,
such a p19ARF function can cause perturbation of ribosomal
biogenesis and activate the L11-Mdm2-p53 pathway. However,
whereas p19ARF can cause ribosome biogenesis stress per se,
it is dispensable for the induction of p53 resulting from such
stress, as demonstrated by the unaltered p53 response and
L11-Mdm2 binding on nucleolar stress in p19ARF/ MEFs. In
addition, even thoughMdm2C305F/C305F MEFs lack p53 response
to Act D treatment, the binding of Mdm2C305F mutant protein to
p19ARF remains intact.
Oncogenic c-MYC can induce p53 through p19ARF indepen-
dent pathways (Zindy et al., 1998). In support, c-MYC expression
elicited ample p53 response in p19ARF null MEF cells
(Figure 6B). Given the role of c-MYC in promoting ribosomal
biogenesis, this p19ARF independent induction of p53 by
c-MYCmay very well be ribosomal protein mediated. This notion
suggests that p53 can safeguard against c-MYC tumorigenesis
via two independent signaling pathways, a p19ARF-Mdm2-p53
pathway and a ribosomal protein-Mdm2-p53 pathway (Fig-
ure 7B). Accordingly, disruption of either one will accelerate
c-MYC-induced tumor formation. This was illustrated by remark-
ably similar short survival time of Em-Myc;Mdm2C305F/C305F
mice and Em-Myc;p19ARF/ mice. Given the data showing
similar susceptibility of Em-Myc;Mdm2C305F/C305F and Em-Myc;
p19ARF/ transgenic animals to tumor development, one
prediction will be that an even shorter latency of Myc-driven
tumor formation might be found in compound mice carrying
both Mdm2C305F/C305F mutation and p19ARF deletion. In conclu-
sion, our data support a model that the p19ARF-Mdm2-p53 and
the RP-Mdm2-p53 pathways are independent, parallel path-
ways working together to protect cells from oncogenic c-MYC-
induced tumorigenesis (Figure 7B).
The Mdm2C305F knockin mouse model provides evidence for
a prevailing in vivo checkpoint, mediated by L11-Mdm2 interac-
tion, to monitor the integrity of ribosome biogenesis and activate
p53 when this process goes awry. The L11-Mdm2-p53 signaling
pathway is not required for DNA damage induction of p53, in that
the mutant mice respond to DNA damage and induce p53
activity as efficiently as their wild-type counterparts. Moreover,
our data establish the L11-Mdm2-p53 pathway as an important
in vivo barrier for defending against oncogenic c-MYC-induced
tumorigenesis, parallel to the p19ARF-Mdm2-p53 signaling.
p19ARF, through interactionwithMdm2,mediates a p53-depen-
dent checkpoint in response to a broad range of oncogenic
insults, including elevated expression of Myc, E2F1, RAS, E1A,
and v-Abl (Sherr, 1998). In this sense, it is conceivable that
L11-Mdm2-p53 signaling also mediates a p53-dependent
checkpoint in response to deregulated oncogenes that promote
superfluous ribosome biogenesis. For instance, E2F1 specifi-
cally interacts with and enhances rRNA promoter activity
through two E2F1-binding sequences (Ayrault et al., 2006);
oncogenic RAS influences mTOR activity and thus protein trans-
lation through modulating the PI3K-Akt signaling cascade
(Fingar and Blenis, 2004). In both cases the oncogenic activity
of E2F1 and RAS promotes ribosomal biogenesis either directly
or indirectly. Whether the L11-Mdm2-p53 signaling is a general
oncogenic surveillance signaling that responses to a broadc.
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only specific to c-MYC remains to be determined.
EXPERIMENTAL PROCEDURES
Generation of Mdm2C305F Knockin Mice
Murine 129/Sv genomic DNA containing the last six exons (exons 7–12) of
Mdm2 was a gift from Dr. Lozano (University of Texas, M.D. Anderson Cancer
Center). The targeting vector was constructed in a PGK neo vector backbone.
A cysteine to phenylalanine substitution was introduced in codon 305 (C305F)
using site-directed mutagenesis (TGT > TTT). A new Spe1 restriction site (ACT
AGT) was generated at the same time (TGT ACC TCA > TTT ACT AGT). DNA
isolated from G418-resistant ES cell colonies was subjected to BamH1 diges-
tion followed by Southern blot analysis using a probe covering intron 9
between exons 9 and 10. The presence of the C305F substitution was further
confirmed by PCR amplification of genomic DNA using primers flanking exon
12, followed by Spe1 digestion. One positive clone was injected into blasto-
cysts, and transferred into pseudopregnant female recipients. Germline
transmission was confirmed by Southern blot and PCR analysis. Neomycin
selection marker was deleted by crossing germline transmitted Mdm2+/C305F
mice with Ella-Cre transgenic mice (Jackson Laboratories, stock number
003724). The resulting males were mated with C57BL/6 females and back-
crossed to C57BL/6 for five generations.
Mouse Experiments
Mice were bred and maintained strictly under protocol (07-056) approved by
the Institutional Animal Care and Use Committee in the University of North
Carolina Animal Care Facility. For BrdU incorporation experiment, mice were
injected intraperitoneally with BrdU (50 mg/g body weight) 30 min before
euthanasia. BrdU incorporation was detected by immunohistochemical stain-
ing of paraffin-embedded tissue sections with mouse anti-BrdU (Ab-2) mono-
clonal antibody (Calbiochem, San Diego, CA), biotin-conjugated anti-mouse
antibody (Vector Laboratories, Burlingame, CA) and an avidin-biotin-peroxi-
dase kit (Vectastain Elite, Vector Laboratories) with diaminobenzidine as
a chromogen. The percentage of BrdU positive cells from the total number
of interfollicular keratinocytes in 200 mm fields and 15 fields per mouse were
quantified. For mouse skin treatments, mice from each genotype were shaven
24 hr before treatment. The dorsal skin was treated topically for 18 hr with
a single dose of Act D at 1 ug/200 ul in acetone or acetone only. For apoptosis
studies, TUNEL assay was carried out using an ApopTag Peroxidase In Situ
Apoptosis Detection Kit (Calbiochem, S7100). For c-MYC-mediated tumori-
genesis study, Mdm2C305F/C305F females were bred with Em-Myc transgenic
males to obtain Em-Myc;Mdm2+/C305F offspring, which were then crossed
with Mdm2C305F/C305F mice to obtain Em-Myc;Mdm2C305F/C305F compound
mice. Em-Myc mice were purchased from Jackson Laboratory (002728). For
survival study, mice were palpated regularly for early signs of inguinal lymph
node enlargement and monitored for tumor progression and signs of
morbidity. Moribund mice were humanely euthanized by CO2 asphyxiation
followed by a secondmethod to ensure euthanasia. Mouse tumors and organs
were fixed in formalin for histopathology and snap frozen for protein and RNA
extraction.
Cell Culture
Primary mouse embryo fibroblasts (MEF) were isolated on embryonic (E) day
13.5 and grown in a 37C incubator with 5% CO2 in DMEM supplied with
10% FBS and penicillin-streptomycin. MEF cells were treated as indicated
with 5 nM or 200 nM actinomycin D (Act D), 2 mM mycophenolic acid (MPA),
1 mM doxorubicin (Dox), or 10 mM 5-fluorouracil (5-FU). For retrovirus infec-
tions, Mdm2+/+, Mdm2C305F/C305F, and p19ARF/ MEF cells were infected
with retroviruses expressing c-MYC or pBabe control vector and selected
with puromycin (2.5 ug/ml) for 3 days. Retrovirus infected MEFs were then
allowed to recover for 48 hr and harvested for analysis.
Protein Analysis
For western blot, MEF cells were lysedwith 0.5%NP-40 lysis buffer for straight
westerns or 0.1% NP-40 lysis buffer for coimmunoprecipitation experiments.
For mouse tissue protein extraction, spleens, thymus, and lymphoma tissuesCanwere ground by pestle and mortar with liquid N2 and the protein was extracted
with 0.5% NP-40 lysis buffer. For protein analysis of epidermal keratinocytes,
the epidermal skin layer was scraped off excised skin using a razor blade and
extracted with 0.5% NP-40 lysis buffer. To assess the half-life of p53 and
Mdm2, low passage MEF cells were treated with cycloheximide (50 ug/ml),
chased for the indicated time points, and harvested with SDS lysis buffer
(2% SDS, 10% glycerol, 50 mM Tris). Mouse monoclonal anti Mdm2 (2A10
and 4B11, Calbiochem), p53 (NCL-505, Novocastra; DO-1, Lab Vision/
Neomarkers), actin (MAB1501, Chemicon International), goat polyclonal anti
p53 (FL-393; Santa Cruz), and rat polyclonal anti p19ARF (Santa Cruz) anti-
bodies were purchased commercially. Rabbit polyclonal antibodies to p21
were gifts from Dr. Yue Xiong (UNC-Chapel Hill). Rabbit polyclonal antibodies
to L5 and L11 were made in house and previously described (Lindstrom
et al., 2007).Cellular Fractionation
Protocol for nucleolar fractionation was adapted from a previously described
method by Muramatsu et al. (1974). Freshly harvested mouse spleens were
mechanically disassociated between two glass microscope slides. Large
debris was allowed to settle and single cell suspension was centrifuged at
2003 g for 10min andwashed 23with RPMI (Roswell ParkMemorial Institute)
medium. Red blood cell lysis was carried out using NH4Cl lysis buffer (0.75%
NH4Cl, 0.017 M Tris-HCl, pH 7.2) for 5 min at room temperature. Splenocytes
were resuspended in 1 ml of RSB buffer (10 mM HEPES, pH 7.9, 10 mM KCl,
1.5 mM MgCl2, 0.5 mM DTT) and placed on ice for 10 min. Cell membranes
were then broken using a Dounce homogenizer (tight pestle A). Nuclei (pellet)
were collected by centrifugation at 2183 g for 5 min and resuspended in 3 ml
of 0.25 M sucrose/10 mM MgCl2 and overlaid onto 3 ml of 0.88 M sucrose/
0.05 mMMgCl2 and purified by centrifugation at 14303 g for 10 min. The pel-
leted nuclei were resuspended in 2 ml of 0.34 M sucrose/0.05 mM MgCl2 and
sonicated for 60 s with 10-s intervals. The sonicated cell lysate was then over-
laid onto 3 ml of 0.88 M sucrose/0.05 mM MgCl2 and centrifuged at 3000 3 g
for 10 min. The pellet contained the purified nucleoli and the supernatant rep-
resented the nucleoplasmic fraction. Protease inhibitor cocktail was added
freshly to all buffers before use.Statistical Analysis
Statistical analysis was carried out using GraphPad Prism 4 Software (Graph-
Pad Software, San Diego, CA). For Em-Myc tumorigenesis experiments a
Kaplan-Meier survival curve was carried out. A one-way analysis of variance
test with Tukey’s multiple comparison posttest was carried out for BrdU
incorporation experiments.ACKNOWLEDGMENTS
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